SK Plasma exports blood products worth 30 million Singapore dollars to Singapore

SK Plasma is set to export blood products to the Singapore region.

On the 28th, SK Plasma announced that it has obtained product approval for albumin and immunoglobulin from the Singapore Health Sciences Authority (HSA) and will begin full-scale production within this month. SK Plasma plans to start exporting initial shipments in the fourth quarter and will exclusively supply blood products worth a total of 30 million Singapore dollars (approximately 29 billion KRW) over the next six years. If the blood product contract manufacturing is successfully carried out for three years, the contract may be extended for an additional three years. The Singapore health authority will supply plasma secured through blood centers within Singapore, and SK Plasma will use this plasma as raw material to produce finished blood products such as albumin at its Andong plant and ship them to Singapore.

Blood products are pharmaceuticals derived from blood, manufactured by fractionating and purifying components within the blood to produce medicines such as albumin and immunoglobulin. They are essential treatments used in various fields including shock due to excessive bleeding, congenital immunodeficiency diseases, and hemophilia. Additionally, blood products are designated and managed as national essential medicines because they become widely necessary in national disaster situations.

Accordingly, the Singapore government has been promoting a project to procure blood products through national tenders and supply them to its citizens. In 2021, SK Plasma was selected as the first Asian company to be entrusted with the full volume of blood products supplied by the Singapore authorities through the national tender for blood products.

SK Plasma plans to contract manufacture and export approximately 20,000 liters of blood products annually to Singapore, utilizing plasma from Singapore that has been received since last year for production. Furthermore, the company intends to accelerate its global business by collaborating with overseas countries to introduce local raw plasma and promote contract manufacturing.

Kim Seung-joo, CEO of SK Plasma, stated, “This blood product contract manufacturing is the first exclusive contract manufacturing export to a country with European Union (EU) Good Manufacturing Practice (GMP) standards, recognizing SK Plasma’s technological capabilities. Based on this achievement, we will continue to expand our global business.”

Meanwhile, SK Plasma is also advancing plans to build a blood product factory in Indonesia. Last month, construction began on a blood product plant near Jakarta capable of processing 1 million liters of plasma raw material annually, with completion targeted for 2025.

This content was produced with the assistance of AI translation services.